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Introduction
Platelet-activating factor (PAF) is a phospholipid mediator 
and cell signaling molecule which displays multiple biological 
and pathophysiological attributes, running the gamut from 
inflammation to cell differentiation and proliferation [1-4]. As is 
well-known, PAF interacts with specific membrane PAF-receptors 
(PAF-Rs) to initiate all cellular responses via specific G-protein-
coupled receptors [1-4]. Although these initiated membrane 
receptor phenomena are mostly established for several tissue-
cell systems [1-8], exactly how PAF and PAF-Rs cause vascular 
remodeling in hypertension and atherosclerosis is not clear. A 
little more than 15 years ago, PAF was identified as a molecule 
that stimulated activation of  nuclear factor-kappaB (NF-kB) [1, 
2, 8].
NF-kB, magnesium deficiency,  PAF and sphingolipids
NF-kB is now known to be a prime regulator of  growth processes, 
differentiation, cell migration, and cell death [for reviews, see [9-
12], all factors required for vascular remodeling in hypertension 
and atherogenesis [13, 14]. NF-kB is clearly a major transcription 
factor and a pleiotrophic regulator of  numerous genes involved 
in inflammatory processes and epigenetic phenomena [9-12, 15]. 
NF-kB is now thought to be a pivotal molecule in atherogenesis, 
hypertension, cardiac failure and stroke [14-19]. As of  now, 
it is still not clear as to what factor(s) initiates expression of  
these molecular events. We were the first laboratory to suggest 
and provide evidence for a role for activation of  NF-kB in the 
cardiovascular manifestations, particularly atherogenesis, noted 
in magnesium deficiency (MgD) [20-22]. We demonstrated 
that when vascular smooth muscle (VSM) cells were exposed 
to low concentrations of  extracellular, ionized Mg ([Mg2+]0), a 
concentration-dependent upregulation of  NF-kB took place; the 
lower the [Mg2+]0, the faster and greater the upregulation of  NF-
kB [20-22]. A similar situation appears to have been reported for 
endothelial cells [23]. Recently, we have reported that lowering 
[Mg2+]0 also results in a synthesis and release of  activated PAF 
[24] concomitant with an upregulation of  five major sphingolipid 
enzymatic pathways responsible for formation of  ceramide and 
sphingosine, prior to NF-kB upregulation [18, 20, 21, 24-31].
Magnesium deficiency and activation of  sphingolipid 
pathways in cardiovascular tissues and cells
The de novo synthesis of  sphingomyelin is brought about 
via the action of  serine palmitoyl-CoA transferase (SPT), 
3-ketosphinganine reductase, ceramide synthase (CS), 
dihydroceramide desaturase, and SM synthase (SMS; ref  [32]). 
SMS requires phosphatidylcholine (PC) and ceramide as substrates 
to manufacture SM and diacylglycerol (DAG; see ref. [32]). This 
reaction directly affects SM, PC, and ceramide as well as DAG levels 
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in cells. Two of  us [21, 33] have previously noted, using primary 
cerebral, coronary, and peripheral VSM cells in culture, as well as 
intact ventricular and atrial myocardial muscle obtained from rats 
after 21 days of  short-term MgD [25-37], that variation of  [Mg2+]0 
influences the cellular levels of  SM, PC, DAG, sphingosine, and 
ceramide. Our in vitro and in vivo studies clearly demonstrated that 
low [Mg2+]0 resulted in cellular synthesis and release of  ceramide 
due to upregulation of  SPT 1 and SPT 2, CS, SMS synthase, and 
a "salvage pathway" [25-31]. Ceramide is now thought to play 
important roles in fundamental pathophysiologic processes such 
as cell proliferation, membrane-receptor functions, angiogenesis, 
atherogenesis, immune inflammatory responses, cell adhesion, 
programmed cell death (i.e., apoptosis), and senescence among 
other functions [18, 25-31, 33-39]. It should be recalled, here, that 
MgD environments, both in vivo and in vitro, have repeatedly been 
shown to produce arterial and arteriolar contraction, vasospasm 
and vascular remodeling [18, 20, 22, 40-51], which we have 
demonstrated to involve ceramide (and other sphingolipids), PAF, 
cellular entry and intracellular release of  free Ca2+, and activation 
of  PKC isozymes, mitogen-activated protein kinases (MAPKs), 
MAPK kinases, tyrosine protein kinases, P-I-3 kinases, and PAF 
among other cellular signaling molecules [18, 24, 33, 40-51].
PAF, magnesium deficiency, ceramide, and activation of  
proto-oncogenes
The proto-oncogene families, particularly c-fos and c-jun, are 
two principal players in regulation of  cell growth, differentiation, 
cell migration, and cell death; all important factors in vascular 
remodeling, as particularly observed in  at herogenesis, 
hypertension, and cardiac failure [11, 13, 14]. It is, however, not 
clear how these proto-oncogenes are activated in vascular disease 
processes. Approximately 15 years ago, we discovered that low 
[Mg2+]0  resulted in upregulation of  both c-fos and c-jun in several 
types of  VSM cells; the lower the [Mg2+]0, the faster and the greater 
the magnitudes of  the upregulation of  these two proto-oncogenes 
[22]. In addition, we found that rats given diets reduced in Mg for 
21 days resulted in upregulation of  c-fos and c-jun in ventricular 
and atrial myocardial muscle cells [29]. Reduction in extracellular 
calcium levels resulted in inhibition of  these events [22]. Very 
recently, we reported that exposure of  several types of  primary 
cultured VSM cells, from at least three different mammalian 
species, to low [Mg2+]0 promoted synthesis and release of  PAF 
and ceramide prior to upregulation of  the proto-oncogenes [24]. 
In very recent experiments, we found that use of  several different, 
specific antagonists of  PAF-Rs attenuated, greatly, the PAF-
stimulated formation of  the proto-oncogenes and ceramide in 
several types of  primary cultured VSM cells, pointing to a novel, 
new pathway in MgD [[24]; unpublished findings ].
Conclusions
We believe our new findings on PAF, proto-oncogenes, and 
sphingolipids, e.g, ceramide and sphingosine, probably point to 
fundamental roles for the upstream regulation of  both proto-
oncogenes and sphingolipids in both VSM and cardiac muscle 
cells. These new, exciting findings probably will also be helpful 
in explaining many of  the known cardiovascular manifestations 
of  MgD, particularly vascular remodeling seen in atherosclerosis 
and hypertension. Last, but not least, our new studies should 
be useful in future studies designed to counteract many of  the 
cardiovascular manifestations of  MgD.
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